Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
 - Enterprise Value to FCFF (EV/FCFF)
 - Return on Equity (ROE) since 2012
 - Return on Assets (ROA) since 2012
 - Debt to Equity since 2012
 - Price to Operating Profit (P/OP) since 2012
 - Price to Book Value (P/BV) since 2012
 - Price to Sales (P/S) since 2012
 - Analysis of Revenues
 - Analysis of Debt
 
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
- Current Ratio
 - The current ratio displayed moderate fluctuation over the observed periods, generally staying below 1. From early 2021 through mid-2022, there was a gradual increase, peaking near 0.96 by December 2022. Following that peak, a downward trend is noticeable, with the ratio declining to a low of 0.65 in September 2024 before showing a slight rebound to 0.74 by mid-2025. This pattern indicates some volatility in short-term liquidity, suggesting challenges in covering current liabilities with current assets in the later periods.
 - Quick Ratio
 - The quick ratio exhibited a similar trend to the current ratio but maintained a lower level throughout the timeframe. Initial growth occurred from 0.61 in March 2021 to around 0.69 by the end of 2022. Subsequently, there was a marked decline beginning in early 2023, reaching roughly 0.44 by late 2024. Despite a minor improvement towards mid-2025, the ratio remained below earlier highs. This decline suggests a weakening in the company's ability to meet short-term obligations without relying on inventory sales.
 - Cash Ratio
 - The cash ratio showed significant variability, with values mostly below 0.5 across all periods, indicating limited immediate cash availability relative to current liabilities. After peaking at 0.44 in March 2024, the ratio dropped sharply to as low as 0.14 by mid-2025. The earlier periods showed some improvement from 0.31 in early 2021 to 0.38 by September 2023, but the downward movement afterward highlights a reduction in the most liquid assets, potentially raising concerns regarding the company's capacity to cover obligations using only cash and cash equivalents.
 
Current Ratio
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Current ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q2 2025 Calculation
            Current ratio = Current assets ÷ Current liabilities
            =  ÷  = 
2 Click competitor name to see calculations.
Over the observed period, current assets display fluctuations with a generally moderate upward trend reaching a peak of 38,871 million US dollars in the first quarter of 2024, followed by a decline in subsequent quarters to 27,675 million US dollars in the third quarter of 2024 before stabilizing around 29,000 million US dollars towards mid-2025.
Current liabilities also exhibit variability, initially decreasing from nearly 32,000 million US dollars in early 2021 to a low near 29,500 million in late 2021, then rising substantially to a peak exceeding 43,000 million US dollars in the third quarter of 2024. This is followed by a reduction to about 36,400 million US dollars in early 2025 before increasing again to nearly 40,000 million US dollars by mid-2025.
The current ratio mirrors these movements, generally remaining below 1.0 throughout the entire period, indicating that current liabilities consistently exceed current assets. It begins around 0.83 in early 2021, temporarily improves to slightly above 1.0 in the third quarter of 2021 but then declines again below 1.0. From 2022 onwards, the current ratio oscillates mostly between 0.65 and 0.96, hitting the lowest point of 0.65 in the third quarter of 2024. This suggests ongoing liquidity pressures with limited short-term financial cushion.
- Current Assets
 - Show moderate growth with peaks and troughs; the highest level was observed in Q1 2024, followed by decreases and relative stabilization.
 - Current Liabilities
 - Experience greater volatility and an overall upward trend with notable peaks in late 2023 and mid-2024, implying increased short-term obligations.
 - Current Ratio
 - Persistent sub-1.0 values indicate potential liquidity concerns, with intermittent minor improvements but a general weakening of the company's ability to cover short-term liabilities with current assets.
 
In summary, the data reveal a company managing sizable and fluctuating current liabilities, with current assets not consistently maintaining a sufficient level to improve liquidity ratios significantly. The suboptimal current ratio throughout the periods warrants attention to short-term financial risk management strategies.
Quick Ratio
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cash and equivalents | ||||||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||||||
| Total quick assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Quick ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q2 2025 Calculation
            Quick ratio = Total quick assets ÷ Current liabilities
            =  ÷  = 
2 Click competitor name to see calculations.
- Total Quick Assets
 - The total quick assets exhibit a fluctuating trend over the period analyzed. Initial values start near 19.4 billion USD and experience moderate increases and decreases throughout. There is a notable peak in the first quarter of 2024, reaching approximately 30.0 billion USD, followed by a considerable decline in subsequent quarters, ending at around 19.1 billion USD by mid-2025. This pattern suggests periods of increased liquidity interspersed with contractions, possibly indicative of strategic liquidity management or fluctuations in receivables and other liquid assets.
 - Current Liabilities
 - Current liabilities generally show an increasing tendency from roughly 32.0 billion USD in early 2021 to a high point exceeding 41.9 billion USD in mid-2024. After reaching this peak, liabilities decline modestly but remain elevated in the range of 36.4 to 39.8 billion USD through mid-2025. This escalation indicates growing short-term obligations, which may reflect operational expansion, increased payables, or other short-term funding requirements.
 - Quick Ratio
 - The quick ratio fluctuates between 0.43 and 0.75 over the observed timeframe. Early 2021 values hover around 0.6 to 0.75, reflecting a moderate ability to cover current liabilities with quick assets. The ratio decreases sharply starting in late 2023 into 2024, falling below 0.5, indicating a weakening liquidity position where quick assets are less sufficient to meet current liabilities promptly. This decline, despite some recovery mid-period, suggests increased liquidity risk or tighter working capital conditions in recent quarters.
 - Summary Insights
 - The company's liquidity positions, as evidenced by total quick assets and the quick ratio, display variability with a general weakening trend in the most recent periods. While total quick assets reached a high in early 2024, current liabilities increased more aggressively, resulting in a deteriorated quick ratio. This divergence points to possible challenges in maintaining sufficient short-term liquidity to cover obligations, raising considerations for cash flow management and short-term financial stability.
 
Cash Ratio
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cash and equivalents | ||||||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||||||
| Total cash assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Cash ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q2 2025 Calculation
            Cash ratio = Total cash assets ÷ Current liabilities
            =  ÷  = 
2 Click competitor name to see calculations.
- Total Cash Assets
 - The total cash assets displayed significant fluctuations over the observed quarters. Early in the timeline, cash balances ranged between approximately $7.5 billion and $12.2 billion, showing volatility but generally maintaining a moderate level. A notable peak occurred in the quarter ending September 2023, reaching nearly $13.3 billion, followed by a further increase to over $18 billion by March 2024. After this peak, there was a marked decline through late 2024 and into 2025, with cash assets dropping as low as $5.5 billion in June 2025 before a slight recovery to around $6.5 billion in the subsequent quarter. This pattern indicates episodes of substantial cash accumulation followed by drawdowns, possibly reflecting cyclical operational or investment activities.
 - Current Liabilities
 - Current liabilities showed a generally rising trend across the periods. Starting at around $31.9 billion in the first quarter of 2021, the liabilities experienced some short-term decreases but largely increased over time, peaking near $43.1 billion by September 2024. The highest levels were observed in late 2023 and early 2024, with values consistently above $41 billion. After the peak, there was a mild decrease into mid-2025, though the liabilities still remained elevated relative to earlier years. This upward trend in current liabilities might indicate growing short-term financial obligations or increased operational scale requiring more working capital.
 - Cash Ratio
 - The cash ratio, indicative of the company's liquidity position relative to its current liabilities, exhibited considerable variability but with an overall declining trend in later periods. Initially, the ratio fluctuated around 0.3 to 0.4, with some peaks reaching 0.44 in early 2024. However, from mid-2024 onwards, the cash ratio decreased significantly, falling to as low as 0.14 by mid-2025. Despite occasional minor rebounds, liquidity levels appear to have weakened relative to current liabilities in the most recent quarters. This decline suggests increased pressure on the company’s immediate liquidity, potentially heightening solvency risk or signaling a strategic allocation of cash to other uses.
 - Summary Insight
 - The data reveals that while cash assets have experienced periods of accumulation, particularly in early 2024, the company also faced rising current liabilities over the timeframe. The deceleration in the cash ratio in later quarters highlights a reduction in liquid resources relative to obligations, indicating tighter short-term financial flexibility. The combination of rising liabilities and diminishing liquidity ratios points to a potential need for careful cash management going forward to ensure adequate coverage of near-term commitments.